+

MX2020013853A - Compuestos innovadores. - Google Patents

Compuestos innovadores.

Info

Publication number
MX2020013853A
MX2020013853A MX2020013853A MX2020013853A MX2020013853A MX 2020013853 A MX2020013853 A MX 2020013853A MX 2020013853 A MX2020013853 A MX 2020013853A MX 2020013853 A MX2020013853 A MX 2020013853A MX 2020013853 A MX2020013853 A MX 2020013853A
Authority
MX
Mexico
Prior art keywords
compounds
novel compounds
compositions
combinations
antitrypsin
Prior art date
Application number
MX2020013853A
Other languages
English (en)
Inventor
John Liddle
Kate Smith
Alexis Denis
Nerina Dodic
David Lomas
Original Assignee
Ucl Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1810290.5A external-priority patent/GB201810290D0/en
Priority claimed from GBGB1906708.1A external-priority patent/GB201906708D0/en
Application filed by Ucl Business Ltd filed Critical Ucl Business Ltd
Publication of MX2020013853A publication Critical patent/MX2020013853A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a compuestos, composiciones, combinaciones y medicamentos que contienen dichos compuestos y procesos para su preparación. La invención también se refiere al uso de dichos compuestos, combinaciones, composiciones y medicamentos, por ejemplo, como moduladores de alfa 1 antitripsina y para el tratamiento de enfermedades asociadas con alfa antitripsina, particularmente enfermedades del hígado.
MX2020013853A 2018-06-22 2019-06-21 Compuestos innovadores. MX2020013853A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1810290.5A GB201810290D0 (en) 2018-06-22 2018-06-22 Novel Compounds
GBGB1906708.1A GB201906708D0 (en) 2019-05-13 2019-05-13 Novel compounds
PCT/GB2019/051761 WO2019243841A1 (en) 2018-06-22 2019-06-21 Novel compounds

Publications (1)

Publication Number Publication Date
MX2020013853A true MX2020013853A (es) 2021-05-27

Family

ID=67139769

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013853A MX2020013853A (es) 2018-06-22 2019-06-21 Compuestos innovadores.

Country Status (10)

Country Link
US (3) US20210276952A1 (es)
EP (1) EP3810131A1 (es)
CN (1) CN113286586A (es)
AU (2) AU2019289228B2 (es)
BR (1) BR112020026314A2 (es)
CA (1) CA3103920A1 (es)
IL (1) IL279526A (es)
MX (1) MX2020013853A (es)
SG (1) SG11202012765PA (es)
WO (1) WO2019243841A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021006392A2 (pt) 2018-10-05 2021-07-06 Vertex Pharma moduladores da alfa-1 antitripsina
GB201820450D0 (en) 2018-12-14 2019-01-30 Z Factor Ltd Compound and its use for the treatment of alpha1-antitryspin deficiency
UY38696A (es) 2019-05-14 2020-11-30 Vertex Pharma Moduladores de alfa-1 antitripsina
GB201918410D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB201918416D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
GB201918414D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
GB201918404D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of aplha1-antitrypsin deficiency
GB201918413D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
CN115768772A (zh) * 2020-04-03 2023-03-07 弗特克斯药品有限公司 作为用于治疗α-1抗胰蛋白酶缺乏症(AATD)的α-1抗胰蛋白酶调节剂的吡喃并[4,3-b]L吲哚衍生物
IL296920A (en) * 2020-04-03 2022-12-01 Vertex Pharma Indole derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)
MX2022012095A (es) * 2020-04-03 2023-01-11 Vertex Pharma Moduladores de alfa-1-antitripsina.
US20230159504A1 (en) * 2020-04-03 2023-05-25 Vertex Pharmaceuticals Incorporated 7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (aatd)
CN115715292A (zh) * 2020-04-03 2023-02-24 弗特克斯药品有限公司 作为用于治疗α-1-抗胰蛋白酶缺乏症(AATD)的α-1-抗胰蛋白酶调节剂的1H-吡唑并[4,3-g]异喹啉和1H-吡唑并[4,3-g]喹啉衍生物
GB202009074D0 (en) 2020-06-15 2020-07-29 Z Factor Ltd Compound
GB202108523D0 (en) 2021-06-15 2021-07-28 Z Factor Ltd Compositions and their use for the treatment of alpha1-antitrypsin deficiency
CN113801053B (zh) * 2021-11-01 2023-09-08 上海皓鸿生物医药科技有限公司 一种制备7-氟-2-氧代吲哚啉-4-羧酸的方法
WO2025049936A1 (en) 2023-08-31 2025-03-06 Biomarin Pharmaceutical Inc. Solid forms of n-1-(2-chloro-3-fluorophenyl)-1-hydroxypentan-2-yl)-7-fluoro-2-oxoindoline-4-carboxamide and methods of their preparation
WO2025049912A1 (en) 2023-08-31 2025-03-06 Biomarin Pharmaceutical Inc. Methods of manufacturing highly stereochemically pure inhibitors of z-at polymerization
WO2025049929A1 (en) * 2023-08-31 2025-03-06 Biomarin Pharmaceutical Inc. Dosage forms of n-(1-(2-chloro-3-fluorophenyl)-1-hydroxypentan-2-yl)-7-fluoro-2-oxoindoline-4-carboxamide and methods of their preparation and use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3818830A1 (de) * 1988-06-03 1989-12-14 Boehringer Mannheim Gmbh Bicyclische carboxamide, verfahren zu ihrer herstellung, deren vorstufen, und diese verbindungen enthaltende arzneimittel
KR100321649B1 (ko) 1993-03-17 2002-07-22 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 에스테르,아미드또는머캅토에스테르로부터유도된분산보조제를함유하는에어로졸제제
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US7232818B2 (en) * 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
US9801637B2 (en) 2006-03-13 2017-10-31 Pneumrx, Inc. Genetically-associated chronic obstructive pulmonary disease treatment
EP2114141A2 (en) 2007-01-10 2009-11-11 University of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
KR101402702B1 (ko) 2011-09-15 2014-06-05 (주)알테오젠 신규한 알파-1 안티트립신 변이체, 이의 제조방법 및 용도
CA3006930A1 (en) * 2015-12-03 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
CN113801053B (zh) 2021-11-01 2023-09-08 上海皓鸿生物医药科技有限公司 一种制备7-氟-2-氧代吲哚啉-4-羧酸的方法

Also Published As

Publication number Publication date
SG11202012765PA (en) 2021-01-28
CA3103920A1 (en) 2019-12-26
WO2019243841A1 (en) 2019-12-26
CN113286586A (zh) 2021-08-20
BR112020026314A2 (pt) 2021-03-30
AU2025200968A1 (en) 2025-03-06
AU2019289228A1 (en) 2021-01-21
US11919856B2 (en) 2024-03-05
US20240400513A1 (en) 2024-12-05
AU2019289228B2 (en) 2024-11-14
IL279526A (en) 2021-01-31
EP3810131A1 (en) 2021-04-28
US20210276952A1 (en) 2021-09-09
US20220340525A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
MX2020013853A (es) Compuestos innovadores.
DOP2018000240A (es) Derivados de piridiniltriazol sustituidos con amida y usos de estos
EA201990495A1 (ru) Биарильные соединения, применимые в качестве иммуномодуляторов
PH12017501921A1 (en) Novel compounds
MY198425A (en) Glp-1 Compositions and uses Thereof
DOP2019000206A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
MX2019014514A (es) Compuestos para tratar la enfermedad de huntington.
GEP20207147B (en) Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
BR112016028255A2 (pt) agentes imunorreguladores
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
EA202090448A1 (ru) Дигидрооксадиазиноны
UY37221A (es) Derivados de feniltriazol sustituidos con amida y usos de estos
MX2019008256A (es) Derivados de bis-heteroarilo biciclicos como moduladores de agregacion de proteinas.
CL2022001178A1 (es) Ligandos de la pseudoquinasa tyk2
PH12021550872A1 (en) Therapeutic compounds
TR201900148T4 (tr) Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
MX2019013419A (es) Compuestos plaguicidas biciclicos.
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
MX2017016231A (es) Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina.
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
NZ760781A (en) Process for the preparation of standardized composition of arjunoglucoside from the bark of terminalia arjuna
PH12020550549A1 (en) Compositions for preventing or treating lupus
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载